ArticleBMC pediatrics2025
Circulating fibroblast growth factor-21, Omentin-1, and betatrophin and their association with metabolic parameters in Saudi adolescents post 12-month lifestyle change program.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundFibroblast growth factor-21 (FGF21) and omentin-1 have been recognized as potent antidiabetic agents with potential hepatoprotective activity. The aim of this study was to evaluate the associations between betatrophin, hepatic FGF21 and omentin-1 as predictive markers of insulin resistance in adolescents who underwent a 12-month lifestyle change intervention program.
methodsProspective data of 218 Saudi adolescents (45 normal and 77 overweight, and 96 obese) (mean age = 15.1 ± 1.5 years and mean BMI = 35.1 ± 6.6 kg/m
resultsResults showed that betatrophin level decreased in the obese and prediabetic groups (p = 0.03, p = 0.002 respectively). There was a significant decrease in BMI in obese and overweight participants after the 12-month lifestyle modification program [35.1 ± 6.6 & 33.1 ± 7.5 and 26.6 ± 1.5 & 25.6 ± 2.3, p < 0.05 and p < 0.01 respectively]. Follow-up omentin1 was significantly elevated in overweight and obese individuals but no significant difference in omentin-1 in prediabetic group at follow-up was observed (p > 0.05).
conclusionWe concluded that betatrophin levels had an inverse association with metabolic biomarkers omentin-1, FGF-21, and 25(OH)D after a 12-month lifestyle modification program. A healthy diet and exercise are associated with decreased betatrophin levels and improving glucose tolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.